JWH-184

JWH-184 is a synthetic cannabinoid from the naphthoylindole family. It acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with a binding affinity of 9.0 nM at CB1 and 2.94 nM at CB2. JWH-184 is one of the cannabinoids identified in herbal incense blends, and is illegal in some countries.

Chemistry

JWH-184 is a member of the naphthoylindole family of synthetic cannabinoids. It is structurally related to other synthetic cannabinoids such as JWH-018 and JWH-073. The compound is named after the initials of its creator, John W. Huffman, a professor of organic chemistry at Clemson University who first synthesized these compounds for research purposes.

Pharmacology

JWH-184 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors. The CB1 receptor is primarily located in the brain, while the CB2 receptor is found mainly in the immune system. The binding affinity of JWH-184 at the CB1 receptor is 9.0 nM, and at the CB2 receptor is 2.94 nM. This makes it a potent cannabinoid, with effects similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

Legal Status

JWH-184 is considered a controlled substance in several countries due to its potential for abuse and the health risks associated with its use. In the United States, it is classified as a Schedule I controlled substance, making it illegal to manufacture, distribute, or possess without a license. Other countries, such as the United Kingdom and Canada, have also banned the substance.

Health Risks

The health risks associated with JWH-184 use are not fully understood, as there is limited research on this specific compound. However, synthetic cannabinoids in general have been associated with a range of adverse effects, including anxiety, paranoia, hallucinations, and in severe cases, seizures and heart attacks. Long-term use can lead to addiction and withdrawal symptoms.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman

‎

‎